

Supplemental Online Content

Chappell LC, Tucker KL, Galal U, et al; BUMP2 Investigators. Effect of self-monitoring of blood pressure on blood pressure control in pregnant individuals with chronic or gestational hypertension. *JAMA*. doi:10.1001/jama.2022.4726

eFigure. Chart for Interpreting Blood Pressure Reading BUMP2

eTable 1. Secondary Outcomes

eTable 2. Recruitment by Site

eTable 3. Planned Sensitivity Analyses

eTable 4. Secondary Outcomes (Descriptive) for Women With Chronic and Gestational Hypertension

eTable 5. STAI and MARS Questionnaire Measures for Women With Chronic and Gestational Hypertension

eTable 6. Adapted Brief Illness Perception Questionnaire – Chronic Hypertension and Gestational Hypertension

eTable 7. Summary of maternal health-related quality of life measured using EQ-5D-5L instrument in the chronic hypertension cohort and in the gestational hypertension cohort

eTable 8. Adverse Events and Serious Adverse Events for Women With Chronic and Gestational Hypertension

eTable 9. Fidelity to Intervention: Proportion of Completed Home Blood Pressure Measurements (Out of the Number of Days With Expected Readings) for Self-monitoring Group Only

eTable 10. Defined Daily Dose (DDD) Proportions for Antihypertensive Medications Prescribed to Women Between Trial Entry and End of Pregnancy

This supplemental material has been provided by the authors to give readers additional information about their work.

LEVEL	BLOOD PRESSURE /mmHg	ACTION
HIGH	SYS 150 or more OR DIA 100 or more	Your blood pressure is high Sit quietly for 5 minutes then measure it again and send in the reading. Contact your maternity unit for urgent assessment today (within 4 hours) and continue to monitor your BP daily.
RAISED	SYS 140-149 OR DIA 90-99	Your blood pressure is raised Sit quietly for 5 minutes then measure it again and send in the reading. If your repeated reading is raised please contact your maternity unit within 24 hours and continue to monitor your BP daily.
NORMAL	SYS 110-139 OR DIA 70-89	Your blood pressure is normal. Continue blood pressure monitoring and your current care
LOW	SYS 109 or less AND DIA 69 or less	Your blood pressure is low. Repeat once more in 5 minutes. If you are taking blood pressure medication, contact your maternity unit within 24 hours or within 4 hours if you feel unwell (e.g. dizzy or faint). If you are not taking medication and you are feeling well this blood pressure does not need any further action.

eFigure. Chart for interpreting blood pressure reading BUMP2

SYS – systolic, DIA – diastolic

You should seek immediate medical help if you experience any symptoms of pre-eclampsia, which include: severe headache, problems with vision, such as blurred vision or lights flashing before the eyes, severe pain just below the ribs, vomiting, sudden swelling of the face, hands or feet - regardless of your blood pressure readings. If at any time you are concerned about your, or your baby's, health you should contact your community midwife or seek other medical advice.

eTable 1. Secondary Outcomes

Maternal
• Difference in mean diastolic BP between usual care and self-monitoring groups.
• Difference in the mean area under the BP over time curve between usual care and self-monitoring group.
• Difference in the mean proportion of readings above 140mmHg (BP load) between usual care and self-monitoring group.
• Severe hypertension (systolic BP \geq 160 or diastolic BP \geq 110mmHg)
• Serious maternal complications (pre-eclampsia, placental abruption, transient ischemic attack or stroke, pulmonary oedema, renal failure, blood transfusion), death.
• Onset of labour
• Quality of life: EQ-5D-5L
Perinatal
• Gestation at delivery
• Birth weight including centile
• Small for gestational age infants (<10th and <3 rd centile)
• Neonatal admissions including length of stay
• Stillbirth
• Early neonatal deaths • Mode of delivery
Process
• Health Behaviours (Illness perception Questionnaire)
• Fidelity to monitoring schedule
• Adherence to medication: MARS questionnaire
• STAI-6 short form anxiety questionnaire
• Health service costs: outpatient consultations (primary & secondary care), inpatient stays, type and dose of antihypertensive medication. ^a
• Cost per quality-adjusted life year gained over trial period. ^a

^aTo be reported separately

eTable 2. Recruitment by Site

Site	Chronic hypertension			Gestational hypertension		
	Self-Monitoring	Usual Care	Total	Self-Monitoring	Usual Care	Total
	n=233	n=221	n=454	n=197	n=199	n=396
Oxford University Hospitals	15	15	30	36	39	75
Guy's and St Thomas' Hospital	47	44	91	20	22	42
Bart's Health	3	1	4	8	9	17
Wolverhampton	19	20	39	12	13	25
Royal Berkshire	10	9	19	11	11	22
Chelsea and Westminster	11	13	24	5	7	12
Manchester	40	40	80	15	16	31
Whipps Cross	4	9	13	7	5	12
King's College Hospital	14	11	25	9	7	16
West Middlesex	24	20	44	12	12	24
Kingston	7	2	9	10	13	23
St George's	22	23	45	7	3	10
Birmingham Women's	14	9	23	23	14	37
Croydon University Hospital	3	5	8	8	16	24
Stoke Mandeville Hospital	233	221	454	197	199	396

eTable 3. Planned Sensitivity Analyses

	Self-Monitoring	Usual Care	Adjusted mean difference for Self-Monitoring vs. Usual Care (95% CI)	p value
Chronic hypertension	n=233	n=221		
Clinic-measured systolic blood pressure readings only				
Mean (SD) systolic blood pressure	131.9 (9.2)	131.5 (9.7)	0.47 (-1.06 to 1.99) ^a	0.55
Highest systolic clinic blood pressure measurement				
Mean (SD) systolic blood pressure	151.4 (15.5)	151.6 (15.6)	0.19 (-2.52 to 2.90) ^a	0.89
Gestational hypertension	n=197	n=199		
Clinic-measured systolic blood pressure readings only				
Mean (SD) systolic blood pressure	133.4 (10.1)	133.8 (9.5)	-0.88 (-2.91 to 1.15) ^b	0.39
Highest systolic clinic blood pressure measurement				
Mean (SD) systolic blood pressure	147.1 (15.9)	148.3 (14.2)	-1.43 (-4.59 to 1.73) ^b	0.38
Adjusted for baseline covariates that predict missingness of primary outcome				
Mean (SD) systolic blood pressure	137.6 (12.1)	137.2 (10.8)	-0.02 (-2.29 to 2.24) ^c	0.98
Test for interaction between cohorts				
Chronic hypertension			0.07 (-1.87 to 2.00)	0.87 ^e
Gestational hypertension			-0.18 (-2.28 to 1.92)	
Combined cohorts (chronic and gestational hypertension)	n=430	N=420		
	135.5 (11.3)	135.3 (11.1)	-0.13 (-1.57 to 1.30) ^d	0.86

^a Estimated from linear mixed effects model adjusting for mean baseline systolic blood pressure, parity and recruitment site. N=10 participants not included in the model due to missing baseline systolic blood pressure.

^b Estimated from linear mixed effects model adjusting for mean baseline systolic blood pressure, parity, transfer from BUMP1 and recruitment site. N=6 participants not included in the model due to missing baseline systolic blood pressure.

^c Estimated from linear mixed effects model adjusting for mean baseline systolic blood pressure, parity, gestational weeks at entry, transition from BUMP1 and recruitment site. N=6 participants not included in the model due to missing baseline systolic blood pressure.

^d Estimated from linear mixed effects model adjusting for mean baseline systolic blood pressure, parity and recruitment site. N=17 participants not included in the model due to missing baseline systolic blood pressure.

^e Linear mixed-effects model of mean SBP modelled against an interaction between randomised group and subgroup indicator, parity site, and transition from BUMP1.

eTable 4. Secondary Outcomes (Descriptive) for Women With Chronic and Gestational Hypertension

	Chronic hypertension		Gestational hypertension	
	Self-Monitoring	Usual Care	Self-Monitoring	Usual Care
	n=233	n=221	n=197	n=199
Onset of labour				
Spontaneous	13 (5.6%)	21 (9.5%)	31 (15.7%)	44 (22.1%)
Induction	108 (46.4%)	101 (45.7%)	95 (48.2%)	88 (44.2%)
Stimulation of labour	2 (0.9%)	3 (1.4%)	3 (1.5%)	1 (0.5%)
Pre-labour Caesarean section	105 (45.1%)	90 (40.7%)	68 (34.5%)	64 (32.2%)
<i>Missing</i>	5	5	0	2
Maternal outcomes for those with primary outcome only (n, % of women)	n=229	n=215	n=187	n=190
One or more serious maternal complication	10 (4%)	17 (8%)	22 (12%)	25 (13%)
Indication for induction of labour or pre-labour Caesarean section^a	n=215	n=194	n=166	n=153
Hypertension-related complication	144 (67.0%)	117 (60.3%)	105 (63.3%)	96 (62.7%)
Other maternal medical complication	27 (12.6%)	34 (17.5%)	22 (13.3%)	15 (9.8%)
Fetal compromise (on scan or cardiotocography)	47 (21.9%)	47 (24.2%)	40 (24.1%)	37 (24.2%)
Breech presentation	8 (3.7%)	5 (2.6%)	5 (3.0%)	4 (2.6%)
Twins		2 (1.0%)	4 (2.4%)	3 (2.0%)
Other fetal/placental complication	13 (6.0%)	13 (6.7%)	10 (6.0%)	10 (6.5%)
Previous Caesarean section	21 (9.8%)	16 (8.2%)	8 (4.8%)	12 (7.8%)
Maternal requests	6 (2.8%)	1 (0.5%)	3 (1.8%)	3 (2.0%)
Reaching 37 weeks' gestation	24 (11.2%)	18 (9.3%)	15 (9.0%)	15 (9.8%)
Other/Missing	3 (1.4%)	2 (1.0%)	3 (1.8%)	2 (1.3%)
Mode of birth (all births from 24 weeks)	(n=233)	(n=221)	(n=209)	(n=207)
Spontaneous vaginal birth	61 (26.2%)	71 (32.1%)	75 (38.1%)	89 (44.7%)
Assisted vaginal birth	18 (7.7%)	18 (8.1%)	17 (8.6%)	17 (8.5%)
Emergency pre-labour caesarean section	61 (26.6%)	46 (20.8%)	34 (17.3%)	36 (18.1%)
Emergency caesarean section in labour	27 (11.6%)	27 (12.2%)	34 (17.3%)	24 (12.1%)
Elective pre-labour caesarean section	65 (27.9%)	58 (26.2%)	49 (24.9%)	40 (20.1%)
<i>Missing</i>	1	1	0	1

^aWomen could have one or more of these.

eTable 5. STAI and MARS Questionnaire Measures for Women With Chronic and Gestational Hypertension

	Self-Monitoring		Usual Care		Adjusted mean difference for Self-Monitoring vs. Usual Care (95% CI)	p value
Chronic hypertension	n=233		n=221			
STAI	n		n			
At enrolment	222	26.5 (18.1)	216	24.7 (19.4)	-	
At 30 weeks	172	27.6 (19.9)	164	25.2 (20.9)	MD 1.81 (-1.94 to 5.56)	0.34
At postnatal follow-up	132	31.9 (17.3)	122	24.1 (20.6)	MD -2.15 (-6.43 to 2.13)	0.33
MARS-5	n		n			
At enrolment	152	23.1 (2.5)	143	23.3 (2.4)	-	
At 30 weeks	138	24.0 (22.0 to 25.0)	127	24.0 (23.0 to 25.0)	MedD 0.00 (-0.43 to 0.43)	>0.99
At postnatal follow-up	116	23.0 (21.0 to 24.0)	94	24.0 (23.0 to 25.0)	MedD -0.50 (-1.38 to 0.38)	0.26
Gestational hypertension	n=197		n=199			
STAI	n		n			
At enrolment	193	29.0 (20.6)	197	26.4 (18.5)	-	
At 30 weeks	122	30.4 (21.7)	126	28.7 (18.9)	MD 0.19 (-4.37 to 4.76)	0.93
At postnatal follow-up	115	25.3 (22.4)	107	26.4 (20.5)	MD -2.13 (-6.93 to 2.68)	0.39
MARS-5	n		n			
At enrolment	31	23.4 (2.8)	31	24.1 (1.7)	-	
At 30 weeks	25	25.0 (22.0 to 25.0)	41	25.0 (24.0 to 25.0)	MedD 0.00 (-1.45 to 1.45)	>0.99
At postnatal follow-up	76	24.0 (22.0 to 25.0)	76	24.0 (22.0 to 25.0)	MedD 0.00 (-1.34 to 1.34)	>0.99

Summary statistics are shown as mean (SD) or median (IQR). STAI: State-Trait Anxiety Inventory. MARS: Medication Adherence Rating Scale. MD: mean difference. MedD: median difference

eTable 6a. Adapted Brief Illness Perception Questionnaire – Chronic Hypertension

CH	Self-Monitoring (N=233)			Usual Care (N=221)		
	Baseline	30 week follow-up	Postnatal follow-up	Baseline	30 week follow-up	Postnatal follow-up
1 How confident are you that you can use a blood pressure monitor correctly? (N)	226	176	136	220	170	123
Mean (SD)	9.0 (2.0)	9.4 (1.3)	9.5 (1.2)	9.0 (1.8)	8.4 (2.3)	8.8 (2.2)
2 How confident are you that you can accurately measure your blood pressure at home?	227	175	136	220	170	122
Mean (SD)	9.0 (1.9)	9.4 (1.4)	9.5 (1.2)	8.9 (1.9)	8.4 (2.2)	8.6 (2.5)
3 How well do you feel you understand your blood pressure?	227	176	136	218	170	123
Mean (SD)	8.4 (2.2)	9.0 (1.5)	8.9 (1.5)	8.3 (2.2)	8.1 (2.3)	8.2 (2.1)
4 How much control do you feel you have over your blood pressure?	226	175	135	220	169	124
Mean (SD)	6.0 (2.7)	6.5 (2.5)	6.3 (2.5)	6.0 (2.6)	6.0 (2.7)	5.9 (2.5)
5 How concerned are you about your blood pressure?	227	175	134	220	170	124
Mean (SD)	2.8 (2.4)	4.2 (2.9)	4.5 (3.0)	2.7 (2.4)	3.8 (2.7)	4.3 (2.9)
6 How much do you think your treatment can help manage your blood pressure?	227	174	134	220	169	121
Mean (SD)	8.2 (2.0)	8.3 (1.8)	7.7 (2.4)	8.1 (2.3)	7.9 (2.3)	7.8 (2.5)
Combined Score^a						
Mean (SD)	43.5 (7.8)	46.8 (6.7)	46.8 (6.2)	43.0 (7.6)	42.6 (8.8) ^b	43.6 (7.9) ^c

^a Combined score is sum of individual component with q5 (concern) reversed. Maximum 60, higher reflects greater confidence in ability to manage hypertension

^b and ^c $p < 0.001$ for mean differences: Linear mixed effects model of adapted brief illness perception questionnaire score at 30 weeks and postnatal follow-up modelled against randomised arm, time point, an interaction between randomised arm and time point, parity, and baseline adapted brief illness perception questionnaire as fixed effects; site as a random effect, and a random intercept for each participant.

eTable 6b. Adapted Brief Illness Perception Questionnaire – Gestational Hypertension

GH	Self-Monitoring (N=233)			Usual Care (N=221)		
	Baseline	30 week follow-up	Postnatal follow-up	Baseline	30 week follow-up	Postnatal follow-up
1 How confident are you that you can use a blood pressure monitor correctly? (N)	196	125	115	199	128	109
Mean (SD)	8.6 (2.0)	9.3 (1.3)	9.5 (1.0)	8.7 (2.1)	8.0 (3.0)	8.1 (2.9)
2 How confident are you that you can accurately measure your blood pressure at home?	196	124	115	199	128	109
Mean (SD)	8.7 (2.0)	9.2 (1.3)	9.5 (1.1)	8.8 (2.0)	8.0 (3.0)	8.0 (3.0)
3 How well do you feel you understand your blood pressure?	195	124	114	199	127	109
Mean (SD)	7.5 (2.6)	8.5 (1.8)	8.6 (1.6)	7.9 (2.3)	7.5 (2.7)	7.6 (2.3)
4 How much control do you feel you have over your blood pressure?	195	125	115	199	127	108
Mean (SD)	5.5 (2.6)	6.0 (2.5)	6.1 (2.2)	5.6 (2.5)	5.6 (2.3)	5.6 (2.4)
5 How concerned are you about your blood pressure?	196	125	115	199	127	108
Mean (SD)	4.2 (3.1)	4.7 (3.1)	5.9 (3.5)	4.2 (3.0)	4.9 (2.9)	5.6 (3.2)
6 How much do you think your treatment can help manage your blood pressure?	196	124	108	199	126	110
Mean (SD)	7.1 (2.7)	6.7 (3.1)	7.1 (2.9)	6.9 (2.9)	6.5 (3.0)	7.0 (3.1)
Combined Score^{a*}						
Mean (SD)	41.7 (8.5)	44.3 (7.7)	46.6 (6.2)	42.0 (8.2)	40.6 (10.4) ^b	42.0(10.5) ^c

^aCombined score is sum of individual component with q5 (concern) reversed. Maximum 60, higher reflects greater confidence in ability to manage hypertension

^b and ^c p<0.001 for mean differences: Linear mixed effects model of adapted brief illness perception questionnaire score at 30 weeks and postnatal follow-up modelled against randomised arm, time point, an interaction between randomised arm and time point, parity, and baseline adapted brief illness perception questionnaire as fixed effects; site as a random effect, and a random intercept for each participant.

eTable 7a. Summary of Maternal Health-Related Quality of Life Measured Using EQ-5D-5L Instrument in the Chronic Hypertension Cohort

	Self-monitoring (n=233)		Usual care (n=221)		Mean difference (95% CI) ^a
	n	Mean (SD)	n	Mean (SD)	
<i>Complete cases</i>					
At enrolment	230	0.840 (0.167)	216	0.851 (0.174)	
At 30 weeks	177	0.761 (0.207)	170	0.801 (0.159)	-0.021 (-0.055 to 0.013)
At postnatal follow-up	129	0.848 (0.199)	118	0.857 (0.147)	-0.002 (-0.040 to 0.035)
	n	Mean (SE)	n	Mean (SE)	Mean difference (95% CI) ^a
<i>Multiple imputation^b</i>					
At enrolment	233	0.839 (0.011)	221	0.850 (0.012)	
At 30 weeks	233	0.759 (0.015)	221	0.792 (0.012)	-0.026 (-0.059 to 0.008)
At postnatal follow-up	233	0.837 (0.016)	221	0.857 (0.012)	-0.016 (-0.053 to 0.021)
	n	Mean (SD)	n	Mean (SD)	Mean difference (95% CI) ^a
<i>Sensitivity Analysis^b</i>					
<i>Complete cases</i>					
EQ-5D-5L baseline	230	0.840 (0.167)	216	0.851 (0.174)	
EQ-5D-5L baseline to 3 months	115	0.788 (0.173)	109	0.813 (0.148)	-0.015 (-0.053 to 0.023)
EQ-5D-5L 3 months to 6 months	101	0.783 (0.234)	97	0.806 (0.171)	-0.012 (-0.064 to 0.039)
EQ-5D-5L 6 months to 12 months	76	0.830 (0.208)	64	0.860 (0.148)	-0.019 (-0.068 to 0.031)
	n	Mean (SE)	n	Mean (SE)	Mean difference (95% CI) ^a
<i>Multiple imputation^b</i>					
EQ-5D-5L baseline	233	0.839 (0.011)	221	0.851 (0.012)	
EQ-5D-5L baseline to 3 months	233	0.784 (0.015)	221	0.800 (0.015)	-0.009 (-0.049 to 0.031)
EQ-5D-5L 3 months to 6 months	233	0.784 (0.020)	221	0.798 (0.017)	-0.010 (-0.058 to 0.038)
EQ-5D-5L 6 months to 12 months	233	0.815 (0.021)	221	0.864 (0.016)	-0.040 (-0.090 to 0.011)

EQ-5D-5L: EuroQol five-level health-related quality of life instrument; SD: standard deviation; SE: standard error ^a

^aAdjusted for centre, parity and potential EQ-5D-5L index baseline imbalances

^b See Appendix Text S1 for details of multiple imputation and sensitivity analyses

eTable 7b. Summary of Maternal Health-Related Quality of Life Measured Using EQ-5D-5L Instrument in the Gestational Hypertension Cohort

	Self-monitoring (n=197)		Usual care (n=199)		Mean difference (95% CI) ^a
	n	Mean (SD)	n	Mean (SD)	
<i>Complete cases</i>					
At enrolment	191	0.788 (0.210)	192	0.804 (0.161)	
At 30 weeks	50	0.768 (0.185)	62	0.771 (0.168)	0.024 (-0.039 to 0.086)
At postnatal follow-up	115	0.827 (0.207)	106	0.846 (0.180)	-0.014 (-0.062 to 0.033)
	n	Mean (SE)	n	Mean (SE)	Mean difference (95% CI) ^a
<i>Multiple imputation^b</i>					
At enrolment	197	0.786 (0.015)	199	0.804 (0.012)	
At 30 weeks	197	0.767 (0.024)	199	0.738 (0.022)	0.041 (-0.026 to 0.107)
At postnatal follow-up	197	0.834 (0.016)	199	0.841 (0.016)	0.003 (-0.041 to 0.047)
	n	Mean (SD)	n	Mean (SD)	Mean difference (95% CI) ^a
<i>Sensitivity Analysis^b</i>					
<i>Complete cases</i>					
EQ-5D-5L baseline	191	0.788 (0.210)	192	0.804 (0.161)	
EQ-5D-5L baseline to 3 months	104	0.814 (0.194)	100	0.815 (0.186)	0.004 (-0.046 to 0.053)
EQ-5D-5L 3 months to 6 months	32	0.815 (0.247)	40	0.821 (0.180)	0.011 (-0.090 to 0.112)
EQ-5D-5L 6 months to 12 months	11	0.805 (0.122)	8	0.874 (0.113)	-0.076 (-0.258 to 0.107)
	n	Mean (SE)	n	Mean (SE)	Mean difference (95% CI) ^a
<i>Multiple imputation^b</i>					
EQ-5D-5L baseline	197	0.786 (0.015)	199	0.803 (0.012)	
EQ-5D-5L baseline to 3 months	197	0.813 (0.018)	199	0.819 (0.018)	0.001 (-0.047 to 0.043)
EQ-5D-5L 3 months to 6 months	197	0.814 (0.034)	199	0.813 (0.024)	0.008 (-0.071 to 0.086)
EQ-5D-5L 6 months to 12 months	197	0.805 (0.037)	199	0.874 (0.040)	-0.076 (-0.268 to 0.116)

EQ-5D-5L: EuroQol five-level health-related quality of life instrument; SD: standard deviation; SE: standard error^a

^aAdjusted for centre, parity, transition from BUMP1 and potential EQ-5D-5L index baseline imbalances

^b See Appendix Text S1 for details of multiple imputation and sensitivity analyses

eTable 8. Adverse Events and Serious Adverse Events for Women With Chronic and Gestational Hypertension

	Self-Monitoring	Usual Care	p value^b
Chronic hypertension	n=233	n=221	
Number of participants experiencing an Adverse Event ^a	3 (1.3)	0	0.25
Number of participants experiencing a Serious Adverse Event	4 (1.7)	2 (0.9)	0.69
Relatedness to intervention (for Serious Adverse Events)	0	0	
	Self-Monitoring	Usual Care	
Gestational hypertension	n=197	n=199	
Number of participants experiencing an Adverse Event ^a	2 (1.0)	0	0.25
Number of participants experiencing a Serious Adverse Event	4 (2.0)	1 (0.5)	0.21
Relatedness to intervention (for Serious Adverse Events)	0	0	

^a Clinically judged to be caused by the trial intervention

^b From Fisher's exact test

eTable 9. Fidelity to Intervention: Proportion of Completed Home Blood Pressure Measurements (Out of the Number of Days With Expected Readings) for Self-monitoring Group Only

	Chronic hypertension	Gestational hypertension	Overall
Proportion of days with completed home blood pressure readings (fidelity)	n=233	n=197	n=430
Number available	n=211	n=154	n=365
Median (IQR)	59.6% (30.9 to 80.7)	57.1% (32.3 to 79.6)	58.8% (32.3 to 80.2)
Transitioned from BUMP1		n=131	n=131
Number available	-	n=94	n=94
Median (IQR)	-	50.9% (27.5 to 76.2)	50.9% (27.5 to 76.2)
Recruited de novo into BUMP2	n=233	n=66	n=299
Number available	n=211	n=60	n=271
Median (IQR)	59.6% (30.9 to 80.7)	66.7% (41.7 to 80.9)	62.0% (37.9 to 80.7)
Time (days) between raised blood pressure on home and clinic measurements^a	n=233	n=197	n=430
Number available	n=161	n=98	n=259
Median (IQR)	14 (0 to 44)	1 (-1 to 6)	5 (-1 to 28)
1st trimester (0+0 to 12+6 weeks)			
Number available	n=17	n=0	n=17
Median (IQR)	6 (1 to 58)	-	6 (1 to 58)
2nd trimester (13+0 to 25+6 weeks)			
Number available	n=118	n=11	n=129
Median (IQR)	15 (-2 to 47)	13 (0 to 62)	15 (-1 to 47)
3rd trimester (26+0 weeks to end of pregnancy)			
Number available	n=26	n=87	n=113
Median (IQR)	16 (6 to 30)	1 (-1 to 5)	2 (-1 to 9)

^a Positive indicates raised blood pressure at home happened after clinic. Negative indicates raised blood pressure at home happened before clinic.

eTable 10. Defined Daily Dose (DDD) Proportions for Antihypertensive Medications Prescribed to Women Between Trial Entry and End of Pregnancy

	Self-monitoring	Change in mean DDD proportion (95% CI)	Usual Care	Change in mean DDD proportion (95% CI)
Chronic Hypertension				
<i>20-weeks</i>	n=109*		n=102*	
Mean (SD) DDD proportion	0.921 (0.606)		0.894 (0.588)	
<i>30-weeks</i>	n=151*	Between 20-30 weeks	n=132*	Between 20-30 weeks
Mean (SD) DDD proportion	1.082 (0.660)	0.161 (0.003 to 0.319)†	1.001 (0.684)	0.107 (-0.060 to 0.274)
<i>End of pregnancy</i>	n=183*	Between 30 weeks and end of pregnancy	n=172*	Between 30 weeks and end of pregnancy
Mean (SD) DDD proportion	1.213 (0.709)	0.131 (-0.018 to 0.280)	1.158 (0.676)	0.157 (0.002 to 0.312)†
Gestational Hypertension				
<i>20-weeks</i>	n=3*		n=3*	
Mean (SD) DDD proportion	0.556 (0.192)		0.611 (0.481)	
<i>30-weeks</i>	n=27*	Between 20-30 weeks	n=25*	Between 20-30 weeks
Mean (SD) DDD proportion	0.852 (0.399)	0.296 (-0.188 to 0.780)	0.893 (0.528)	0.282 (-0.377 to 0.941)
<i>End of pregnancy</i>	n=129*	Between 30 weeks to end of pregnancy	n=117*	Between 30 weeks to end of pregnancy
Mean (SD) DDD proportion	1.040 (0.616)	0.188 (-0.057 to 0.433)	1.066 (0.533)	0.173 (-0.059 to 0.405)

DDD: Defined Daily Dose; SD: standard deviation

*Number of women in the trial at time point with an ongoing pregnancy and prescribed antihypertensive medication.

†p<0.05